Choline kinase inhibitory effect and antiproliferative activity of new 1,1′,1″-(benzene-1,3,5-triylmethylene)tris{4-[(disubstituted) amino]pyridinium} tribromides

European Journal of Medicinal Chemistry

Volumn 38, Issue 1, 2003, Pages 109-116

  Conejo García, Ana ^a   Campos, Joaquín ^a   Sánchez, Rosario M ^a   Rodríguez González, Agustín ^b   Lacal, Juan C ^b   Gallo, Miguel A ^a   Espinosa, Antonio ^a  

^a Facultad de Farmacia   (Spain)

^b CSIC   (Spain)

Author keywords

Antiproliferative agents; Bispyridium; HT 29; Human choline kinase; Trispyridinium

Indexed keywords

1,1' (BENZENE 1,3 DIMETHYLENE)BIS[4 (PIPERIDINO)PYRIDINIUM]DIBROMIDE; 1,1' (BENZENE 1,3 DIYLMETHYLENE)BIS[(4 DIMETHYLAMINO)PYRIDINIUM]DIBROMIDE; 1,1' (BENZENE 1,3 DIYLMETHYLENE)BIS[4 (N METHYLANILINO)PYRIDINIUM]DIBROMIDE; 1,1' (BENZENE 1,3 DIYLMETHYLENE)BIS[BIS[4 (PYRROLIDINO)PYRIDINIUM]]DIBROMIDE; 1,1',1'' (BENZENE 1,3,5 TRIMETHYLENE)TRIS[4 (3,5 DICHLORO N METHYLANILINO)PYRIDINIUM]; 1,1',1'' (BENZENE 1,3,5 TRIYLMETHYLENE)TRIS[(4 DIMETHYLAMINO)PYRIDINIUM)]TRIBROMIDE; 1,1',1'' (BENZENE 1,3,5 TRIYLMETHYLENE)TRIS[4 (4 CHLORO N METHYLANILINO)PYRIDINIUM]TRIBROMIDE; 1,1',1'' (BENZENE 1,3,5 TRIYLMETHYLENE)TRIS[4 (N METHYLANILINO)PYRIDINIUM]TRIBROMIDE; 1,1',1'' (BENZENE 1,3,5 TRIYLMETHYLENE)TRIS[4 (PIPERIDINO)PYRIDINIUM]TRIBROMIDE; 1,1',1'' (BENZENE 1,3,5 TRIYLMETHYLENE)TRIS[4 (PYRROLIDINO)PYRIDINIUM]TRIBROMIDE; BROMINE DERIVATIVE; CHOLINE KINASE; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; ENTROPY; ENZYME INHIBITION; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BROMIDES; CELL DIVISION; CHOLINE KINASE; DRUG DESIGN; HT29 CELLS; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PYRIDINIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037367431     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(02)00004-1     Document Type: Article

References (28)

1. Goldberg D.M., Diamandis E.P. Clin. Chem. 39:1993;2360-2374.
2. Weber G. Cancer Res. 43:1983;3466-3492.
3. Schapira F. Isozymes Curr. Top. Biol. Med. Res. 5:1981;27-75.
4. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M.M., Bos J.L. New Engl. J. Med. 319:1988;525-532.
5. Denison M.S., Fisher J.M., Whitlock J.P. Jr. J. Biol. Chem. 263:1988;17221-17224.
6. Prochaska H.J., De Long M.J., Talalay P. Proc. Natl. Acad. Sci. USA. 82:1985;8232-8236.
7. Talalay P., De Long M.J., Prochaska H.J. Proc. Natl. Acad. Sci. USA. 85:1988;8261-8265.
8. Hernández-Alcoceba R., Saniger L., Campos J., Núñez M.C., Khaless F., Gallo M.A., Espinosa A., Lacal J.C. Oncogene. 15:1997;2289-2301.
9. Kennedy E.P. Fed. Proc. 20:1961;934-940.
10. Kent C. Prog. Lipid Res. 29:1990;87-105.
11. Vance D.E. Biochem. Cell Biol. 68:1990;1151-1165.
12. Abdellatif M., MacLellan W.R., Schneider M.D. J. Biol. Chem. 269:1994;15423-15426.
13. Barbacid M. Eur. J. Clin. Invest. 20:1990;225-235.
14. Wiesmüller L., Wittinghofer F. Cell. Signal. 6:1994;247-267.
15. Ko K.W.S., Cook H.W., Vance D.E. J. Biol. Chem. 261:1986;7846-7852.
16. Ting Y.L., Sherr D., Degani H. Anticancer Res. 16:1996;1381-1388.
17. Bhakoo K.K., Williams S.R., Florian C.L., Land H., Noble M.D. Cancer Res. 56:1996;4630-4635.
18. Hernández-Alcoceba R., Fernández F., Lacal J.C. Cancer Res. 59:1999;3112-3118.
19. Campos J., Núñez M.C., Sánchez R.M., Gómez-Vidal J.A., Rodríguez-González A., Báñez M., Gallo M.A., Lacal J.C., Espinosa A. Bioorg. Med. Chem. 10:2002;2215-2231.
20. Campos J., Núñez M.C., Rodríguez V., Gallo M.A., Espinosa A. Bioorg. Med. Chem. Lett. 10:2000;767-770.
21. Campos J., Núñez M.C., Rodríguez V., Entrena A., Hernández-Alcoceba R., Fernández F., Lacal J.C., Gallo M.A., Espinosa A. Eur. J. Med. Chem. 36:2001;215-225.
22. Suckling C.J. J. Chem. Soc. Chem. Commun. 12:1982;661-662.
23. Zoltewicz J.A., Deady L.W. Adv. Heterocyclic Chem. 22:1978;71-121.
24. Schnall S., Macdonald J.S. Macdonald J.S., Haller D.G., Mayer R.J. Manual of Oncologic Therapeutics. 1995;170-184 J.B. Lippincott Co, Philadelphia.
25. Viswandadhan V.N., Ghose A.K., Revankar G.R., Robins R.K. J. Chem. Inf. Comput. Sci. 29:1989;163-172.
26. PALLAS FRAME MODULE, a prediction tool of physicochemical parameters, is supplied by CompuDrug Chemistry Ltd., PO Box 23196, Rochester, NY 14692, USA.
27. Lucas L., Hernández-Alcoceba R., Rodríguez P., Lacal J.C. Oncogene. 20:2001;1110-1117.
28. Ramírez de Molina A., Peñalva V., Lucas L., Lacal J.C. Oncogene. 21:2002;937-946.